Menu
Search
|

Menu

Close
X

Apricus Biosciences Inc APRI.OQ (NASDAQ Stock Exchange Capital Market)

1.03 USD
+0.00 (+0.00%)
As of Feb 23
chart
Previous Close 1.03
Open 1.03
Volume 208,590
3m Avg Volume 120,219
Today’s High 1.05
Today’s Low 1.00
52 Week High 3.39
52 Week Low 0.87
Shares Outstanding (mil) 15.22
Market Capitalization (mil) 15.52
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.50 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
5
EPS (USD)
FY17
-0.895
FY16
-1.262
FY15
-3.848
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.62
Price to Sales (TTM)
vs sector
43.60
8.35
Price to Book (MRQ)
vs sector
2.43
5.22
Price to Cash Flow (TTM)
vs sector
--
25.88
Total Debt to Equity (MRQ)
vs sector
0.00
15.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.39
Return on Investment (TTM)
vs sector
-670.74
13.63
Return on Equity (TTM)
vs sector
--
15.39

EXECUTIVE LEADERSHIP

Kleanthis Xanthopoulos
Chairman of the Board, Since 2013
Salary: --
Bonus: --
Richard Pascoe
Chief Executive Officer, Principal Accounting Officer, Secretary, Director, Since 2016
Salary: $473,200.00
Bonus: $88,555.00
Brian Dorsey
Senior Vice President, Chief Development Officer, Since 2014
Salary: $310,000.00
Bonus: $46,500.00
Paul Maier
Independent Director, Since 2012
Salary: --
Bonus: --
Rusty Ray
Independent Director, Since 2013
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

11975 El Camino Real Ste 300
SAN DIEGO   CA   92130-2543

Phone: +1858.2228041

Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company's drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud's phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.

SPONSORED STORIES